title: HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
abstract: An individual's CD8(+)-cytotoxic-T-lymphocyte (CTL) response to Epstein-Barr virus (EBV) latent cycle antigens focuses on a small number of immunodominant epitopes often presented by just one of the available HLA class I alleles; for example, HLA-A11-positive Caucasians frequently respond to two immunodominant HLA A11 epitopes, IVTDFSVIK (IVT) and AVFDRKSDAK (AVF), within the nuclear antigen EBNA3B. Here, we reexamine the spectrum of EBV strains present in the highly HLA-A11-positive Chinese population for sequence changes in these epitopes relative to the Caucasian type 1 prototype strain B95.8. The IVT epitope was altered in 61 of 64 Chinese type 1 viruses, with four different sequence variants being observed, and the AVF epitope was altered in 46 cases with six different sequence variants; by contrast, all 10 Chinese type 2 viruses retained the prototype 2 epitope sequences. All but one of the type 1 epitope variants were poorly recognized by IVT- or AVF-specific CTLs in pulse-chase assays of peptide-mediated target cell lysis. More importantly, we screened HLA-A11-positive Chinese donors carrying viruses with known epitope mutations for evidence of epitope-specific CTL memory by enzyme-linked immunospot assays: none of the type 1 variants tested, nor the type 2 prototype, appeared to be immunogenic in vivo. The data remain consistent with the possibility that, during virus-host coevolution, pressure from the host CTL-mediated immune response has given A11 epitope-loss viruses a selective advantage.
authors.affiliation: CRUK Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom.
authors.forename: R S
authors.initials: RS
authors.lastname: Midgley
authors.forename: A I
authors.initials: AI
authors.lastname: Bell
authors.forename: Q Y
authors.initials: QY
authors.lastname: Yao
authors.forename: D
authors.initials: D
authors.lastname: Croom-Carter
authors.forename: A D
authors.initials: AD
authors.lastname: Hislop
authors.forename: B M
authors.initials: BM
authors.lastname: Whitney
authors.forename: A T C
authors.initials: AT
authors.lastname: Chan
authors.forename: P J
authors.initials: PJ
authors.lastname: Johnson
authors.forename: A B
authors.initials: AB
authors.lastname: Rickinson
mesh_terms: D000595:Amino Acid Sequence; D044466:Asian People; D001483:Base Sequence; D002681:China; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000235:genetics / Q000276:immunology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D014644:Genetic Variation; D015234:HLA-A Antigens / Q000235:genetics / Q000378:metabolism*; D059870:HLA-A11 Antigen; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016056:Immunodominant Epitopes; D008969:Molecular Sequence Data; D011110:Polymorphism, Genetic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: C422762:EBNA-3B antigen; D018984:Epitopes, T-Lymphocyte; D019309:Epstein-Barr Virus Nuclear Antigens; D015234:HLA-A Antigens; D059870:HLA-A11 Antigen; D016056:Immunodominant Epitopes